Dianthus Therapeutics (DNTH) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Dianthus Therapeutics (NASDAQ: DNTH) in the last few weeks:

• 8/6/2026 – Dianthus Therapeutics had its price target raised by Truist Financial Corporation from $110.00 to $128.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Dianthus Therapeutics had its price target raised by HC Wainwright from $130.00 to $158.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Dianthus Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $131.00 price target on the stock.
• 8/5/2026 – Dianthus Therapeutics had its price target raised by Wedbush from $105.00 to $122.00. They now have an “outperform” rating on the stock.
• 7/17/2026 – Dianthus Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity at Dianthus Therapeutics

In related news, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the transaction, the executive vice president directly owned 31,249 shares in the company, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Anne Mcgeorge sold 7,750 shares of Dianthus Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the completion of the sale, the director directly owned 1,250 shares in the company, valued at approximately $136,262.50. This represents a 86.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 287,084 shares of company stock valued at $29,615,923 over the last ninety days. Company insiders own 3.02% of the company’s stock.

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.